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ABSTRACT
Objective Examine the relationship between antibodies
to 25 oral bacteria and pancreatic cancer risk in a
prospective cohort study.
Design We measured antibodies to oral bacteria in
prediagnosis blood samples from 405 pancreatic cancer
cases and 416 matched controls, nested within the
European Prospective Investigation into Cancer and
Nutrition study. Analyses were conducted using
conditional logistic regression and additionally adjusted
for smoking status and body mass index.
Results Individuals with high levels of antibodies
against Porphyromonas gingivalis ATTC 53978, a
pathogenic periodontal bacteria, had a twofold higher
risk of pancreatic cancer than individuals with lower levels
of these antibodies (OR 2.14; 95% CI 1.05 to 4.36;
>200 ng/ml vs ≤200 ng/ml). To explore the association
with commensal (non-pathogenic) oral bacteria, we
performed a cluster analysis and identiﬁed two groups of
individuals, based on their antibody proﬁles. A cluster
with overall higher levels of antibodies had a 45% lower
risk of pancreatic cancer than a cluster with overall lower
levels of antibodies (OR 0.55; 95% CI 0.36 to 0.83).
Conclusions Periodontal disease might increase the risk
for pancreatic cancer. Moreover, increased levels of
antibodies against speciﬁc commensal oral bacteria,
which can inhibit growth of pathogenic bacteria, might
reduce the risk of pancreatic cancer. Studies are needed
to determine whether oral bacteria have direct effects on
pancreatic cancer pathogenesis or serve as markers of the
immune response.
INTRODUCTION
Each year, approximately 40 000 Americans die of
cancer of the pancreas, making pancreatic cancer
the fourth most common cause of cancer-related
mortality.1 Pancreatic cancer is one of the most
rapidly fatal diseases, with fewer than half of
patients surviving past 6 months from diagnosis.
Detection of pancreatic cancer at early stages could
increase survival; however, no biomarker currently
has sufﬁcient sensitivity and speciﬁcity for screen-
ing of pancreatic cancer at the population level.
Consequently, primary prevention of pancreatic
cancer is of particular importance in reducing the
burden of this malignancy.
Signiﬁcance of this study
What is already known about this subject?
▸ Pancreatitis increases the risk of pancreatic
cancer.
▸ Bacteria can disseminate into the pancreas.
▸ Periodontal disease has been associated with
pancreatic cancer.
What are the new ﬁndings?
▸ First study to prospectively examine the
relationship between oral bacteria and
pancreatic cancer risk.
▸ Porphyromonas gingivalis, a periodontal
pathogen, may increase pancreatic cancer.
▸ Oral commensal bacteria may decrease risk of
pancreatic cancer.
How might it impact on clinical practice in
the foreseeable future?
▸ Provide opportunity to better understand which
bacteria are related to risk of pancreatic cancer
and lead to improvement in early detection of
disease.
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A positive association between periodontal disease and pan-
creatic cancer was observed in a prospective cohort study of
men health professionals.2 In this study, men reporting a posi-
tive history of periodontal disease had a 64% higher risk of pan-
creatic cancer compared with those reporting no periodontal
disease; among never smokers, a twofold increase in pancreatic
cancer risk was observed (RR=2.09, 95% CI 1.18 to 3.71),
ruling out the possibility that the overall association was con-
founded by smoking. Other studies reported similar ﬁndings
between periodontal disease3 4 or tooth loss5 and pancreatic
cancer.
The role of bacteria in pancreatic diseases aetiology or
tumour development has been suggested by multiple
approaches. Using molecular methods, Helicobacter genus-
speciﬁc DNA (but not Helicobacter pylori species-speciﬁc DNA)
was identiﬁed in pancreatic cancer tissues,6 while a positive
association between H pylori infection and pancreatic cancer
has been reported in several studies.7 Using culture methods,
the microbiota isolated from the pancreas had similarities to
oral microbiota, particularly in the case of pancreatitis.8–11
Bacteria reaching the pancreatic tissues by dissemination has
been documented in both animal models and human sub-
jects.9 12 13 Additionally, multiple observations have shown that
oral microbiota overlap with the digestive tract microbiota, pro-
viding multiple avenues for dissemination in dysbiosis.14–17 In a
recent retrospective case-control study, oral bacteria measured in
saliva were associated with pancreatic cancer.18
We undertook this study to further investigate the association
between periodontal bacteria and pancreatic cancer risk. Our a
priori hypothesis (NIH R21 grant) was that antibodies to three
periodontal pathogens (Porphyromonas gingivalis, Tannerella
forsythia and Aggregatibacter actinomycetemcomitans) are posi-
tively associated with pancreatic cancer risk. We measured anti-
body levels to 25 oral bacteria, including strains that are
elevated in patients with chronic periodontitis, in plasma
samples collected prior to disease onset in a large European
cohort study. This is the ﬁrst study to examine antibodies to oral
bacteria in relation to pancreatic cancer risk.
MATERIALS AND METHODS
Study population
The European Prospective Investigation into Cancer and
Nutrition (EPIC) includes 519 978 participants, mostly aged
35–70 years, who were recruited in 23 centres within 10
European countries (Denmark, France, Germany, Greece, Italy,
the Netherlands, Norway, Spain, Sweden and the UK) between
1992 and 2000. Detailed descriptions of the study design,
population and baseline data collection of the cohort can be
found in the previous report.19 Each participant provided
informed consent. The local ethical review committees
approved the EPIC cohort study as well as the current project.
Blood sample collection and storage
Collection of blood samples was obtained from 385 747 EPIC
study participants. In all but three countries (Denmark, Norway
and Sweden), blood samples were collected based on a standar-
dised protocol and aliquoted in plastic straws (plasma, serum,
erythrocytes and buffy coat for DNA). The aliquoted specimens
were then stored in a central biorepository (IARC, France) in
liquid nitrogen (−196°C). In Norway the biological samples
were collected in 20 0.5 ml plastic straws; 12 of the 16 plasma
and two of the four buffy coat samples were shipped to IARC
for storage in the central repository. In Sweden, all samples
were stored locally in freezers at −80°C and in Denmark in
nitrogen vapour (−150°C).
Pancreatic cancer ascertainment
In seven of the participating countries (Denmark, Italy, the
Netherlands, Norway, Spain, Sweden and the UK), follow-up of
cancer cases is based on population cancer registries. In France,
Germany, Greece and Naples (one centre in Italy), a combin-
ation of methods are used for follow-up and cancer ascertain-
ment, including health insurance records, cancer and pathology
registries, and active follow-up through study subjects and their
next-of-kin. In all EPIC centres, data on vital status were col-
lected from mortality registries at the regional or national level,
and combined with health insurance data (France) or data col-
lected by active follow-up (Greece). The percentage of subjects
lost to follow-up was 1.6% (loss is due to emigration, study
withdrawal or non-response in active follow-up centres). Cancer
incidence data are coded according to International
Classiﬁcation of Diseases-Oncology second edition and mortal-
ity data according to the International Classiﬁcation of Diseases
tenth edition (ICD-10). Incidence cases of exocrine pancreatic
cancer reported during the study period were eligible for selec-
tion into this study. We excluded participants who had other
malignant tumours preceding the diagnosis of pancreatic cancer,
except for non-melanoma skin cancer. We identiﬁed 578 inci-
dent cases of pancreas cancer that were coded according to
ICD-10 (C25.0–25.3, 25.7–25.9); 468 of these cases had blood
specimens available. For each case, one control subject was
selected (alive and free of cancer at the time that the index case
was diagnosed) using an incident density sampling procedure.
Matching characteristics consisted of: study centre, sex, age at
blood collection, date and time of blood collection, fasting and
exogenous hormone use (women only). For efﬁciency purposes
matching was conducted for several planned cohort analyses
simultaneously; matching factors were selected with consider-
ation of all analyses. Due to insufﬁcient volume or assay failure,
the ﬁnal dataset consisted of 405 cases and 416 control subjects.
Antibody detection
All samples were de-identiﬁed and blinded to case-control status.
Samples were sent to the laboratory in matched pairs so that
assays were consistently conducted on the same day for each pair;
however, the pairs were not kept in the same order (eg, case-
control; case-control; control-case) to maintain blinding. The
presence of antibodies in the plasma samples against a preselected
panel of whole-cell formalin ﬁxed bacterial antigen was tested
using an immunoblot array.20 This method has the advantage of
using a very small amount of primary sample (less than 10 μl).
Bacterial strain selection was based on prior detection in pancre-
atic tissues8–11 and known serotypes for P gingivalis (ATCC
33277 (also known as strain 381), serotype a; ATCC 53978
(also known as the capsulated strain W50), serotype b),21 22 and
A actinomycetemcomitans (ATCC 29523, serotype a; ATCC
43718, serotype b)23 (see table 2 for full list).
On a subset of the case and control subjects (n=532) replicate
measurements of each bacterial strain were performed (see
online supplementary table S1). These were averaged for the
overall analysis and per cent concordance was calculated among
this subset of subjects for each bacterial strain, in the following
ranges of human IgG (ng/ml) antibody levels: 0–7.5; 7.6–50;
50–200; >200 (respectively: no signal detected and to the
lower detection limit of 7.5; (>7.5 to <50 ng/ml) lower range
of the ﬁtted reference curve; within the reference curve; and
higher end of the ﬁtted reference curve to saturation). Percent
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concordance was found to be good for all bacterial strains,
ranging from 0.67 to 0.84 (see online supplementary table S1).
Statistical analysis
Differences between cases and controls across baseline character-
istics were assessed by paired t-tests (continuous variables) or by
McNemar’s test (categorical variables). Continuous measure-
ments of the IgG antibody levels were log transformed to
achieve approximate normality.
To assess the association between individual bacterial strains
suspected to be periodontal pathogens and pancreatic cancer,
we created four categories for the human IgG (ng/ml) based on
the quantitative results from the immunoassays (ranges of
human IgG (ng/ml) antibody levels: no signal detected and to
the lower detection limit of 7.5; lower range of the ﬁtted refer-
ence curve (>7.5 to <50 ng/ml); within the reference curve
(50–200 ng/ml); higher end of the ﬁtted reference curve to sat-
uration >200 ng/ml). We considered values above 200 ng/ml as
seropositive and conducted the main analysis for the pathogens
of interest as a dichotomous variable, comparing values above
to below 200 ng/ml.
Potential confounding effects of factors other than those con-
trolled for by matching (ie, body mass index (BMI), waist cir-
cumference, current and past tobacco smoking and diabetes)
were examined by assessing the association of these factors with
pancreatic cancer risk. We retained smoking and BMI in all
multivariate models; none of the other variables changed the
logistic β estimate by more than 10% (individually or when
included simultaneously). Subjects were deﬁned as diabetics if
they self-reported the condition in the baseline questionnaire at
recruitment. Analyses using unconditional regression models
controlling for matching factors led to similar results; we
present results for the conditional regression analyses.
To avoid multiple comparison issues when examining the
measured oral bacteria antibodies for which we did not have
strong a priori hypotheses (ie, the non-pathogenic periodontal
strains), we used an exploratory analysis to identify groups of
people with similar levels of oral antibodies (using all 25 mea-
sured strains). The cluster analysis was performed in R using the
MCLUST procedure.24 We retained two clusters based on
optimal clustering examining the Bayesian Information
Criterion scores (for more details on cluster analysis refer to
online supplementary method).25 We examined the association
between the two identiﬁed clusters and the risk of pancreatic
cancer using conditional logistic regression.
For the oral pathogens, we performed subgroup analyses to
assess possible effect modiﬁcations by smoking status and age
(median, 62 years); tests for interaction were conducted by
including a product term of the antibodies by smoking and age
in the regression models. In sensitivity analyses, we removed the
ﬁrst 2 years of follow-up after blood collection to address
reverse causality, and separately, removed diabetics for the ana-
lysis as these individuals are at higher risk for periodontal
disease. For these subanalyses we used unconditional logistic
regression to retain power.
All statistical analyses were conducted using the Statistical
Analysis System (SAS) software package, V.9.2 (SAS Institute
Inc., Cary, North Carolina, USA) except for the cluster analysis
which was conducted in R (using RStudio, Inc., V.0.94.110).
RESULTS
Age at blood collection and sex were similar for cases and con-
trols (controls were matched to cases on these factors). Mean
follow-up time was 5.0 years for cases (from time of blood draw
until date of diagnosis); controls had to be alive and free of
cancer at the time the matched case was diagnosed. Cases were
more likely to be current smokers or diabetics than controls,
and had slightly higher BMIs (BMI; table 1). Alcohol intake and
height were similar among cases and controls (table 1).
Characteristics among cases who gave blood were similar to
overall pancreatic cancer cases in the EPIC cohort (blood cases
vs total cases26: eg, diabetes 7.0% vs 7.1%; BMI 26.7 vs 26.2;
males 48% vs 40%; age 57.8 vs 58.1); although current
smoking was somewhat higher in this study (30% blood cases vs
25% all cases).
Plasma antibody detection against 25 oral bacteria was per-
formed. Very high correlations were observed for the two
strains of P gingivalis (ATTC strains 33277 and 53978, r=0.91),
and A actinomycetemcomitans (ATTC strains 29523 and
43718, r=0.94). A high correlation was also noted for the two
species of Veillonella tested (Veillonella atypica and Veillonella
parvula, r=0.88); those species are relatively genetically
distant.27 Most antibodies were correlated to each other,
although strength of correlations varied (see online supplemen-
tary table S2). High antibodies levels (>200 ng/ml) of P gingiva-
lis ATTC 53978 were more common in cases than controls
(p=0.05, table 2), but not for the other P gingivalis strain.
Given our a priori hypothesis that periodontal pathogens are
associated with higher risk for pancreatic cancer, we examined
individual antibodies to those bacteria which have been previ-
ously associated with periodontal tissue destruction, which
include P gingivalis, A actinomycetemcomitans and T forsythia
(ie, ﬁve pathogens in our assay). Of these, the highest concentra-
tion of P gingivalis ATTC 53978 (>200 ng/ml) was associated
with a twofold increased risk of pancreatic cancer (OR=2.14,
95% CI 1.05 to 4.36, compared with levels ≤200 ng/ml; table 3).
The association was similar after removing cases that were
diagnosed within 2 years of blood collection, although it was no
longer statistically signiﬁcant (table 3). Adding a 5 year or 7 year
lag did not weaken the association with P gingivalis, if anything
the association became stronger over time (OR=2.56, 95% CI
0.75 to 8.7 for the 7 year lag). Furthermore, associations were
positive for all three categories of smoking status (never:
OR=2.1, 95% CI 0.9 to 4.9; former: OR=3.2, 95% CI 0.5 to
Table 1 Characteristics of pancreatic cancer cases and control
subjects selected from the European Prospective Investigation into
Cancer and Nutrition cohort for this analysis
Cases Controls p Values*
Numbers 405 416
Males (%) 48.4 47.8
Mean (SD) age at blood collection (y) 57.8 (8.0) 57.8 (7.9)
Smoking status (%) 0.09
Never 36.4 43.0
Past 32.4 34.4
Current 30.0 21.4
Unknown 1.2 1.2
Mean (SD) body mass index (kg/m2) 26.7 (4.3) 25.9 (3.9) 0.01
Mean (SD) height (cm) 168.5 (9.1) 168.2 (9.9) 0.43
Mean (SD) waist circumference (cm) 90.2 (12.5) 88.8 (12.9) 0.11
Mean (SD) alcohol at baseline (g/d) 15.8 (22.2) 15.1 (24.0) 0.88
Diabetes (%) 7.0 4.6 0.17
Postmenopausal (%, among women) 70.3 73.3 0.40
*Paired t-test for continuous variables and McNemar’s test for categorical variables;
p values for variables that were used to match cases and controls are not shown
(ie, sex, age, length of follow-up).
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21; current: OR=2.2, 95% CI 0.5 to 9.4) or after removing dia-
betics (OR=1.7, 95% CI 0.9 to 3.1). Tests for interaction for
smoking, age and diabetes were not statistically signiﬁcant. No
associations were observed for the ﬁve oral pathogens when
using four categories of antibody levels (see online supplemen-
tary table S3).
Given our lack of a priori hypothesis on individual oral bacteria
that are not considered oral pathogens, and given the high corre-
lations observed between these bacteria, we performed clustering
analysis to aggregate individuals depending on their antibody pro-
ﬁles. Two clusters were retained for analysis based on the model
with the lowest BIC score (see online supplementary methods for
more details on cluster analysis). A strong statistically signiﬁcant
inverse association was observed in cluster 2 which identiﬁed
individuals with consistently higher levels of commensal oral bac-
teria antibodies (table 4) compared with cluster 1 (correlations
between individual bacteria and clusters are provided in online
supplementary table S4). In addition, frequencies for individual
commensal oral bacteria by four categories of antibody levels are
provided in online supplementary table S3; the majority of these
associations were inverse, indicating that antibodies to commensal
bacteria are higher in controls than cases.
DISCUSSION
We observed a twofold increase in pancreatic cancer among
individuals who had high levels (>200 ng/ml) of antibodies to
the periodontal pathogen P gingivalis ATTC 53978 compared
with those with lower levels (≤200 ng/ml). In addition, we
Table 2 Percentage of samples with oral bacteria levels above 200 ng/ml by case and control subjects
Bacteria Cases % with IgG levels
>200 ng/ml
Controls % with IgG levels
>200 ng/ml
p Value*
Oral pathogens† (Gram negative)
Porphyromonas gingivalis ATCC 33277 17.3 17.3 1.0
P gingivalis ATCC 53978 7.2 4.6 0.05
Aggregatibacter actinomycetemcomitans ATCC 29523 19.8 21.9 0.45
A actinomycetemcomitans ATCC 43718 20.0 23.8 0.15
Tannerella forsythia ATCC 43037 2.2 2.2 1.0
Oral bacterial species of the human microbiome (Gram negative)
Captonocytophaga ochracea ATCC 33596 30.9 31.3 0.82
Eikenella corrodens ATCC 23834 10.6 12.7 0.31
Fusobacterium nucleatum ATCC 25586 4.4 4.6 0.86
Fusobacterium periodonticum ATCC 33693 0.49 0.24 0.56
Fusobacterium polymorphum ATCC 10953 0.25 0.24 1.0
Prevotella intermedia ATCC 25611 4.7 4.6 0.86
Prevotella melaninogenica ATCC 25845 10.6 11.5 0.51
Prevotella nigrescens ATCC 33563 10.4 12.0 0.30
Veillonella atypica ATCC 17744 0.25 0.25 1.0
Veillonella parvula ATCC 10790 1.0 1.9 0.25
Oral bacterial species of the human microbiome (Gram positive)
Actinomyces naeslundii ATCC 12104 77.5 80.5 0.22
Bifidobacterium dentium ATCC 27534 0.99 0.48 0.41
Corynebacterium matruchotii ATCC 14266 0.74 1.9 0.13
Enterococcus faecalis ATCC 29212 0.25 0.75 0.32
Finegoldia magna ATCC 29328 0.25 0
Parvimonas micra ATCC 33270 47.2 52.2 0.09
Peptostreptococcus anaerobius ATCC 27337 0 0
Streptococcus intermedius ATCC 27335 5.4 5.8 0.86
Streptococcus mitis ATCC 49456 43.7 46.9 0.25
Streptococcus salivarius ATCC 7073 10.6 11.3 0.69
*McNemar’s test.
†Oral bacterial pathogens which have been previously associated with periodontal disease.
Table 3 OR and 95% CI for pancreatic cancer associated with antibody levels to Porphyromonas gingivalis ATTC 53978
Antibody level to P gingivalis ATTC 53978 Case/controls OR (95% CI)* MV OR (95% CI)†
Low levels (≤200 ng/ml) 376/397 1.0 (referent) 1.0 (referent)
High levels (>200 ng/ml) 29/19 2.00 (1.00 to 4.00) 2.14 (1.05 to 4.36)
Removing cases diagnosed within 2 years of blood collection
Low levels (≤200 ng/ml) 304/397 1.0 (referent) 1.0 (referent)
High levels (>200 ng/ml) 25/19 2.10 (0.99 to 4.46) 2.11 (0.97 to 4.59)
*OR and 95% CI were obtained using conditional logistic regression (cases were matched to controls on centre, sex, follow-up time, age at blood collection, date and time of blood
collection, fasting status and use of exogenous hormones among women).
†Multivariate ORs (MV OR) were obtained using conditional logistic regression and additionally adjusting for body mass index (continuous) and smoking status (never, past, current).
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noted that individuals with consistently high levels of antibodies
to common oral bacteria had a 45% lower risk of pancreatic
cancer compared to those with a proﬁle of lower antibody
levels. Antibodies were measured in blood samples that were
collected up to 10 years prior to cancer diagnosis, thereby most
likely minimising changes in immune response that could have
occurred after pancreatic cancer development.
A recent study reported an association between microbiota
and pancreatic cancer using saliva specimens collected after
cancer diagnosis and comparing them to healthy controls (retro-
spective case-control study).18 In this study, microbiota from 10
pancreatic cancer cases were compared to 10 healthy controls,
and validated in 28 independent pancreatic cancer cases and 28
healthy controls. Two bacteria, Neisseria elongata and
Streptococcus mitis, were found to be lower in cases than con-
trols in both datasets. These ﬁndings are similar to ours as we
also observed an inverse association with S mitis (we did not
measure N elongata). Our results, however, suggest that it may
be more than one or two commensal bacteria that are inversely
associated with risk of pancreatic cancer.
Despite a high correlation between the two Porphyromonas
strains measured in this study (r=0.91), high levels of antibodies
to P gingivalis ATCC 53978 (6%) were much less prevalent
than for P gingivalis ATCC 33277 (17%). These two strains are
quite distinct as P gingivalis ATCC 53978 has a capsule known
as a major antigen associated with pathogenicity of the strain,28
while P gingivalis ATCC 33277 lacks this antigen and is minim-
ally inﬂammatory.29 30 Furthermore, these two strains also have
different ﬁmbrial and outer membrane serotypes,21 31 and a set
of common antigens shared among species based on genomic
data. The association between 19 bacterial antibodies and mea-
sured clinical indices of oral health was examined in a large US
population study (the third National Health and Nutrition
Examination Survey).32 Of the 19 antibodies tested, only anti-
body titres to P gingivalis (mixed suspension of ATCC strains
53978 and 33277) were signiﬁcantly higher in individuals with
periodontitis (moderate or severe, and separately for extensive
periodontitis) compared with healthy individuals (p<0.05),32 as
was previously observed in smaller studies.33–36 High levels of
antibodies to P gingivalis ATCC 53978 may be the best antibody
marker for high bacterial load and aggressive periodontal
disease, which is in agreement with the third National Health
and Nutrition Examination Survey data,32 and thus may explain
why it was the only suspected periodontal pathogen associated
with an elevated risk of pancreatic cancer.
P gingivalis ATCC 53978 levels were also elevated in cluster 2
(which was inversely associated with risk of pancreatic cancer),
as most of the other tested bacterial target were elevated in this
cluster. In adults, prevalence of P gingivalis in subgingival
plaques of patients with periodontitis has been found to be
higher than in individuals with healthy gums.36 37 While P gin-
givalis bacterial load is strongly associated with periodontal
pocket depth, prevalence is otherwise similar between patients
and controls with healthy gums indicating the normal presence
of the species in health.38–40 Most recently, a study from the
Human Microbiome Project reported that certain bacterial
genera thought to be composed of pathogenic species present in
periodontal disease (eg, Aggregatibacter, Porphyromonas,
Tannerella and Treponema) were found in at least 93% of indivi-
duals with no gum disease suggesting that these bacterial genera
are also part of the normal oral microbiota and exposed to the
immune system response.41
Oral diseases originate from changes in the ecological balance
of the microbiota,35 42 43 suggesting that there is a beneﬁcial
effect of members of the oral microbiota. Capnocytophaga
ochracea, for example, was signiﬁcantly more prevalent among
healthy patients (>90%) than chronic periodontitis patients
(<60%), and was found at more sites among healthy indivi-
duals.38 In addition, this microbe has been associated with sig-
niﬁcantly less disease progression in other studies.44 45
Veillonella species were, in another study, associated with peri-
odontal health.42 We therefore propose that the inverse associa-
tions observed in our study for cluster 2 may reﬂect individuals
with oral microbial stability, healthy gum status, and a strong
immune response toward bacteria.
Host genetic susceptibility related to immune function could
explain our observations. Recent data from Genome-Wide
Association Studies examining genetic susceptibility and pancre-
atic cancer risk reported that individuals with non-O blood
groups had a higher risk of pancreatic cancer than those with
blood type O.46 Although it is not clear how these ﬁndings
translate to carcinogenesis, SNPs at the ABO gene locus were
found to be determinants of circulating levels of molecules that
are important mediators of chronic inﬂammation and immune
cell recruitment.47–50 The best-established connection between
local inﬂammation and pancreatic cancer comes from studies on
chronic pancreatitis.51 It has been proposed that the prolonged
inﬂammation observed in chronic pancreatitis patients is what
initiates or aids the progression of a pancreatic tumour.52
Culture based studies of pancreatitis have shown a bacterial col-
onisation of the tissues.8–10
Genetic determinants of immune surveillance clearly play a
critical role in pancreatic cancer development. Consequently, it
is plausible that elevated levels of antibodies to oral bacteria in
individuals serve as a marker for a genetically stronger immune
response, providing protection against carcinogenesis. In a study
of periodontal disease and cancer among twins, the associations
with periodontal disease could be partially explained by shared
genetic risk factors.4 As periodontitis is a complex disease of
polymicrobial origins which is inﬂuenced by genetic susceptibil-
ity, host response and environmental factors, deciphering the
genetic component of the disease is still under study.35 53–55
The strength of this study includes a large sample size, pre-
diagnostic bloods and a methodology that enabled us to
measure a large number of antibodies using small volumes of
plasma (as these are valuable resources). By using prediagnostic
bloods, we were able to minimise reverse causation and examine
the association with antibodies many years prior to diagnosis of
cancer. With 405 cases and 416 controls, we had adequate
power to examine a large number of antibodies. Furthermore,
we had detailed data on smoking history and other known risk
factors of pancreatic cancer and conducted multivariate analyses
to rule out potential confounding by these factors.
Table 4 OR and 95% CI for pancreatic cancer associated with
two profiles of antibody response (clusters 1 and 2)
Cluster*
Case/
controls
MV OR
(95% CI)†
1. Low antibody levels to commensal oral
bacteria
192/229 1.0 (referent)
2. High antibody levels tocommensal oral
bacteria
212/187 0.55 (0.36 to 0.83)
*For more details on cluster analysis approach, refer to Supplemental Methods.
†OR and 95% CI were obtained using conditional logistic regression (cases were
matched to controls on centre, sex, follow-up time, age at blood collection, date and
time of blood collection, fasting status and use of exogenous hormones among
women) and adjusting for body mass index and smoking status.
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The two main limitations of this study were lack of gold stand-
ard measurements for the antibodies and having only one blood
measure per subject at one point in time. We could not conduct
ELISA tests to measure antibodies, which are considered the gold
standard measurement, because we did not have sufﬁcient blood
volume in the EPIC samples; however, the methods we used have
been validated in previous studies where blood product amounts
were not a limiting factor. While we only had one measurement
per individual, antibodies to periodontal pathogens have been
shown to be fairly stable over time,33 56 which suggests that our
ﬁndings would be similar if we had more than one measurement
over time. Another limitation of this study was that we did not
have any data on drug use (eg, antibiotics or NSAID use) that
may have inﬂuenced bacteria antibody levels. Similarly, we were
not able to control for chronic pancreatitis as these outcomes
were not ascertained in the EPIC cohort; it is plausible that the
association observed is mediated through pancreatitis, in which
case we would not want to control for this factor. More research
is needed to examine the pathways and mechanisms that may
explain our ﬁndings.
In summary, this is the ﬁrst study to examine antibodies to
oral bacteria and risk of pancreatic cancer. Our ﬁndings suggest
that individuals who have high levels of antibodies to P gingiva-
lis ATTC 53978, a bacterium strongly associated with periodon-
tal tissue destruction, are at higher risk of pancreatic cancer,
while a distinct cluster of individuals with elevated antibodies to
oral bacteria were associated with a lower risk of pancreatic
cancer. Given that this is the ﬁrst study to examine these associa-
tions, they will need to be conﬁrmed in other studies. If con-
ﬁrmed, our ﬁndings may open new avenues to investigating the
role of the oral bacteria and periodontal disease in pancreatic
carcinogenesis and provide exciting opportunities to improve
our understanding of the development of this fatal disease.
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